`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`____________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`____________
`
`EDWARDS LIFESCIENCES CORPORATION, EDWARDS LIFESCIENCES LLC,
`AND EDWARDS LIFESCIENCES AG
`Petitioners
`
`v .
`
`BOSTON SCIENTIFIC SCIMED, INC.
`Patent Owner
`
`____________
`
`Case IPR2017-00060
`Patent 8,992,608
`____________
`
`
`
`SUPPLEMENTAL DECLARATION OF NIGEL P. BULLER, M.D.
`SUBMITTED ON BEHALF OF PETITIONERS EDWARDS LIFESCIENCES
`CORPORATION, EDWARDS LIFESCIENCES LLC, AND
`EDWARDS LIFESCIENCES AG
`
`
`
`
`
`
`
`
`
`
`
`Edwards Lifescience Corporation, et al. Exhibit 1035, p. 1 of 7
`
`
`
`IPR2017-00060
`
`I, Dr. Nigel P. Buller, declare as follows:
`
`1.
`
`I have been retained on behalf of Edwards Lifesciences Corporation,
`
`Edwards Lifesciences LLC and Edwards Lifesciences AG (“Edwards”), and its
`
`counsel, Jeffer Mangels Butler & Mitchell, LLP, as an expert in this proceeding. I am
`
`personally knowledgeable about the matters stated herein and am competent to make
`
`this declaration.
`
`2.
`
`I have been informed that the Patent Owner objected to my qualifications
`
`as an expert as of the asserted June 2004 priority date of U.S. Patent No. 8,992,608 (the
`
`“’608 Patent”) on “any technical matter relevant to transcatheter aortic heart valves,
`
`including, engineering devices for sealing spaces formed by native valve leaflets and
`
`fluid dynamics associated with paravalvular leakage of transcatheter aort heart valves,”
`
`whether the claims of the ’608 Patent are valid, whether a person of ordinary skill
`
`would have been motivated to combine prior art references to disclose the inventions
`
`claimed in the '608 patent, the construction and application of claim terms from the
`
`'608 patent, and whether I have any first-hand knowledge, experience, or perceptions
`
`regarding these issues sufficient to render any lay testimony or opinions on these
`
`matters. As such, I have been asked to provide additional explanation regarding these
`
`topics.
`
`3.
`
`First, I incorporate by reference herein the discussion of my Background
`
`and Qualifications set forth at Paragraphs 5-26 of my Declaration, as well as my
`
`
`
`
`1
`
`
`
`
`
`
`
`Edwards Lifescience Corporation, et al. Exhibit 1035, p. 2 of 7
`
`
`
`IPR2017-00060
`
`Curriculum Vitae attached as Exhibit A to my Declaration, which was submitted as
`
`Exhibit 1007 to IPR2017-00060.
`
`4.
`
`As noted in paragraph 23 of my Declaration, throughout the 1990s, I
`
`served on scientific advisory boards, including Patent Owner Boston Scientific’s
`
`scientific advisory board, where I discussed and debated concepts and development of
`
`a variety of medical devices for use in interventional procedures, including stent-based
`
`devices.
`
`5.
`
`In June of 2004, the asserted priority date of the ’608 Patent, only a
`
`handful of physicians in the world had hands-on experience with transcatheter heart
`
`valve technology, namely interventional cardiologists Dr. Alain Cribier and his team
`
`with respect to aortic transcatheter heart valves and Dr. Philipp Bonhoeffer and his
`
`team with respect to pulmonary transcatheter heart valves. As such, a person of
`
`ordinary skill in the art for purposes of the ’608 Patent would not be limited to
`
`interventional cardiologists with hands-on experience with transcatheter heart valves.
`
`Instead, as set forth in my Declaration at Paragraph 36, a person of ordinary skill in the
`
`art as of June 2004 would be an interventional cardiologist with a working knowledge
`
`of heart valve designs and endovascular prostheses, including expandable stents and
`
`stent-grafts. My Declaration provides summations of my expertise in the areas of heart
`
`valve designs and endovascular prostheses, including expandable stents and stent-
`
`grafts. See Ex. 1007 at Paragraphs 5-26.
`
`
`
`
`2
`
`
`
`
`
`
`
`Edwards Lifescience Corporation, et al. Exhibit 1035, p. 3 of 7
`
`
`
`IPR2017-00060
`
`6.
`
`I further provide that I have been qualified as an expert in a number of
`
`matters involving transcatheter heart valve technology, most recently in a matter where
`
`I served as an expert on behalf of Petitioner Edwards Lifesciences in litigation against
`
`Patent Owner Boston Scientific involving the European counterpart patents to the ’608
`
`Patent, the patent subject here to inter partes review. This and other matters in which
`
`I’ve both submitted expert reports and testified at trial on transcatheter heart valve
`
`technology are provided below:
`
`a. Edwards Lifesciences LLC v. Boston Scientific Scimed, Inc., Case No.
`
`HC-2015-004574 (High Court of Justice Chancery Division, United
`
`Kingdom). The Approved Judgment in this matter, attached as Exhibit
`
`1036 hereto, confirms that I was qualified as an expert witness on
`
`transcatheter heart valve technology. See, e.g., Exhibit 1036 at ¶¶ 47-48.
`
`b. CoreValve Inc. v. Edwards Lifesciences AG, Case No. HC-07-C01243
`
`(High Court of Justice Chancery Division, United Kingdom). The
`
`Judgment in this matter, attached as Exhibit 1037 hereto, confirms that I
`
`was qualified as an expert witness on transcatheter heart valve technology.
`
`See, e.g., Exhibit 1037 at ¶¶ 40-44.
`
`c. Edwards Lifesciences AG v. Cook Biotech Inc., Case No. HC08-00934
`
`(High Court of Justice Chancery Division, United Kingdom). The
`
`Approved Judgment in this matter, attached as Exhibit 1038 hereto,
`
`
`
`
`3
`
`
`
`
`
`
`
`Edwards Lifescience Corporation, et al. Exhibit 1035, p. 4 of 7
`
`
`
`IPR2017-00060
`
`confirms that I was qualified as an expert witness on transcatheter heart
`
`valve technology. See, e.g., Exhibit 1038 at ¶¶ 5-6.
`
`d. Edwards Lifesciences AG v. CoreValve, Inc., C.A. No. 08-091 (GMS) (D.
`
`Del.). The Court’s post-trial memorandum opinion in this matter,
`
`attached as Exhibit 1039 hereto, confirms that I was qualified as an expert
`
`witness on transcatheter heart valve technology. See, e.g., Exhibit 1039 at
`
`7.
`
`e. Edwards Lifesciences LLC v. Medtronic CoreValve LLC, C.A. No. 12-023
`
`(GMS) (D. Del.). There is no post-trial opinion in this matter as it settled
`
`prior to issuance of any such opinion, but Edwards’ post-trial brief in
`
`support of its motion for enhanced damages, attached hereto as Exhibit
`
`1040, confirms that I was qualified as an expert witness on transcatheter
`
`heart valve technology. See, e.g., Exhibit 1040 at 12-13.
`
`7.
`
`I have been informed that the Patent Owner also objected to Exhibit 1015,
`
`Excerpts from Vossoughi et al., Stent Graft Update (2000), submitted on October 12,
`
`2016 in the Petition for Inter Partes Review, and I have been asked to provide
`
`additional information regarding this Exhibit. This textbook is accepted by those of
`
`ordinary skill in the art and in the field of interventional cardiology generally as a
`
`reliable authority and it also is relied on by persons of ordinary skill in the art and in
`
`the field of interventional cardiology. Exhibit 1041 is a true and correct copy of the
`
`complete Stent Graft Update textbook.
`
`
`
`
`4
`
`
`
`
`
`
`
`Edwards Lifescience Corporation, et al. Exhibit 1035, p. 5 of 7
`
`
`
`IPR2017—0006O
`
` L
` accepted bythose ofordinary Skillin the art andIn the field 0f interventlonal
`
`{1:-_ 8 I have been informedthatthe Patent Owner objected to Ex 1016,
`IExcerptsfrornDolmatch et al., Stent Grafts: Current Clinical Practice (1999),
`E‘s‘} submitted on Qctober12, 2016111 the Petition for Inter Partes Review, and I have been
`i asked to prov1de additional information regarding this Exhibit This textbook1S
`
`1' cardiologygenerally as a reliable authority and it also15 relied on by persons of
`“
`
`’7 r _
`skillin,the art and-in the field ofinterventional cardiolOgy. Exhibit 1042 is a
`trueand correctcobyioi‘ithe complete’SLtent Grafts: Current Clinical Practice textbook.
`
`V
`911,11" 1I havebeeninformedthatthe Patent Owner objected to Ex. 1026,
`:1 GoreExcluderInstructions for Use (2002), submitted on October 12, 2016m the
`
`Petitlon for Inter Partes Review, and I have been asked to provide additional
`
`
`
`
`
`15.,JApri125, 2017
`
`J ,1' authority and1talso13relied on bypersons ofordinary skill1n the art and1nthe field
`I . {of Interventmnal cardiology.
`
`.15;
`
`
`
`' Edwards Lifescience Corporation, et a1. Exhiblt 1035, p. 6 of 7
`
`Edwards Lifescience Corporation, et al. Exhibit 1035, p. 6 of 7
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`Pursuant to 37 C.F.R. § 42.6(e), the undersigned certifies that on April 26,
`
`2017, a complete and entire copy of DECLARATION OF NIGEL P.
`
`BUELLER, M.D. has been served in its entirety by e-mail on the following
`
`addresses of record for Patent Owner:
`
`jennifer.sklenar@apks.com
`
`wallace.wu@apks.com
`
`
`
`
`
`/s/ Gregory Cordrey
`Gregory S. Cordrey
`Attorney for Petitioners
`Registration No. 44,089
`
`
`
`
`
`
`
`Edwards Lifescience Corporation, et al. Exhibit 1035, p. 7 of 7
`
`